Much of the controversy surrounding the AAP guidelines appears to stem from a misinterpretation regarding the use of statins and other lipid-lowering drugs. These are options for managing specific genetic hypercholesterolemias such as FH, and severe hypertriglyceridemias. There is no randomized clinical trial data of statin treatment begun in childhood with regard to adult CAD event outcomes and it is unlikely that such data will be forthcoming for decades, if ever. However, the more common dyslipidemias correlated with insulin resistance and obesity should not be routinely managed with drugs, as diet and exercise remain the best treatment choices.
ABOUT THE NATIONAL LIPID ASSOCIATION
The National Lipid Association (NLA) is a multidisciplinary non-profit membership association that serves the community of healthcare professionals who manage patients with lipid disorders and cardiovascular disease. The NLA's public health mission is to help reduce deaths related to high cholesterol. For more information, please see the NLA Web site at: http://www.lipid.org.
| SOURCE National Lipid Association Copyright©2008 PR Newswire. All rights reserved |